In a landmark decision for the treatment of obesity, the U.S. Food and Drug Administration (FDA) has approved the first oral GLP-1 receptor agonist for weight management. Novo Nordisk announced late Monday that its once-daily Wegovy® pill (oral semaglutide 25 mg) has been cleared for long-term weight reduction and the prevention of major cardiovascular events.
The approval marks a significant shift in the weight-loss landscape, offering a non-injectable alternative that delivers results comparable to the widely popular once-weekly Wegovy injections.
Clinical Breakthrough: 16.6% Weight Loss
The FDA’s decision was supported by data from the OASIS clinical trial program. In the OASIS 4 trial, adult participants with obesity or overweight accompanied by at least one weight-related comorbidity achieved a mean weight loss of 16.6% over 64 weeks when adhering to the once-daily 25 mg tablet regimen.
Notably, the study revealed that one in three participants lost 20% or more of their body weight, a level of efficacy previously seen only with injectable therapies. The safety profile of the oral version remained consistent with the well-established semaglutide molecule, with gastrointestinal side effects being the most commonly reported.
Cardiovascular Benefits
Beyond weight loss, the Wegovy pill is indicated to reduce the risk of major adverse cardiovascular events (MACE), including heart attack, stroke, and cardiovascular death. This makes it a dual-purpose treatment for patients with established heart disease who are also struggling with excess weight.
Market Launch and Global Availability
Novo Nordisk expects the Wegovy pill to be available to patients in the United States in early January 2026.
While the U.S. is the first to grant approval, the company has already submitted regulatory filings to the European Medicines Agency (EMA) and other global authorities during the second half of 2025. Currently, the injectable version of Wegovy remains approved in the EU and other regions, while the pill awaits further international clearance.
The introduction of an oral version is expected to significantly increase patient access and adherence, removing the barrier of needle-based administration for millions of individuals managing chronic weight-related conditions.
Last Modified:
BiotechReality Business Intelligence Desk
